Recently Featured

FDA Warns Against The Silver Bullet Due to Hidden Drug Ingredients

May 4, 2026
The Food and Drug Administration (FDA) has issued a public notification advising against the purchase or use of The Silver Bullet, a product marketed for sexual enhancement. This product is available on various online platforms, including eBay, and may also be found in some retail locations. The FDA’s warning stems from the discovery of undisclosed…

Roche Advances MS Drug Fenebrutinib to Regulatory Review Amid Safety Concerns

May 4, 2026
The Swiss drugmaker Roche has presented promising data for its experimental multiple sclerosis drug, fenebrutinib, positioning itself to seek regulatory approval for a treatment aimed at reducing relapse rates and slowing the progression of disability associated with the disease. While the results from three late-stage trials indicate the drug’s efficacy, analysts are raising alarms about…

Kyverna Therapeutics Plans to Submit Cell Therapy for Stiff Person Syndrome for FDA Approval

May 4, 2026
A one-time, personalized cell therapy from Kyverna Therapeutics has demonstrated improved mobility and reduced disabilities in patients suffering from stiff person syndrome, a rare neurological autoimmune disorder, as revealed by recent study results. This advancement marks a significant milestone in the treatment landscape for this challenging condition. Kyverna is preparing to submit this innovative therapy…

Alzheimer’s Linked to Cancer Mutations in Brain Immune Cells

May 3, 2026
New research from Boston Children’s Hospital reveals that microglia, the brain’s resident immune cells, accumulate mutations in specific cancer-driving genes, potentially linking these mutations to the development of Alzheimer’s disease rather than cancer itself. This groundbreaking study, led by Dr. Christopher Walsh and his team, suggests that the same mutations found in blood cancers like…

Ongoing Cases